FASTnet: una piattaforma nazionale per il test EGFR a favore del paziente e del clinico

Translated title of the contribution: FASTnet: A national platform for EGFR testing in favour of the patient and the clinician

Francesca Fenizia, Carmine Pinto, Gaetano De Rosa, Massimo Barberis, Antonio Marchetti, Nicola Normanno

Research output: Contribution to journalArticlepeer-review


During the last decade, new drugs able to interfere with specific neoplastic processes have been developed. Therefore, the possibility of creating a personalized therapeutic scheme, based on the molecular alterations activated in each single tumor, is becoming a clinical reality. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung tumor, representing about 80% of pulmonary cancers. Following the discovery of the role of EGFR gene in tumor growth and development and, later, of activating mutations of this gene, new targeted therapies have been introduced in clinical practice, namely inhibitors of the EGFR tirosin-kinase domain (TKI). First line treatment with TKIs is considered the optimal therapy in patients with metastatic or locally advanced EGFR-M+ NSCLC. For this reason, it is crucial to evaluate EGFR mutational status to identify the most suitable therapeutic approach. The EGFR FASTnet program, started in 2010 with the support of AstraZeneca, is a national network designed to facilitate the exchange of biological material, clinico-pathological data and diagnostic reports between medical oncologists, primary pathologists and referral laboratories through a dedicated website (www.egfrfastnet. it), a call-center and a courier. Starting from July 2010, 12.893 FASTnet forms have been completed and, up to date, 677 oncologists, 153 primary pathologists and 25 analysts are registered to the network and give their active contribute to the mutational analysis workflow. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology - Italian division of International Academy of Pathology (SIAPeC-IAP) have full access to the anonymous EGFR FASTnet database that provides relevant information on molecular pathology in lung cancer in Italy.

Translated title of the contributionFASTnet: A national platform for EGFR testing in favour of the patient and the clinician
Original languageItalian
Pages (from-to)32-36
Number of pages5
JournalRassegna di Patologia dell'Apparato Respiratorio
Issue number1
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'FASTnet: A national platform for EGFR testing in favour of the patient and the clinician'. Together they form a unique fingerprint.

Cite this